As a result, MEDIPOST has become a frontrunner in the field of the biopharmaceuticals not only in Korea but also in the world. MEDIPOST with its state-of-the-art platform technology has led to the development and approval of the world’s first allogeneic stem cell therapy product – CARTISTEM®.
MEDIPOST continues its endeavors on clinical development and commercialization of stem cell therapeutics to improve quality of lives of many patients with intractable diseases not only in Korea, but also around the globe.
21, Daewangpangyo-ro 644 (Sampyeong-dong), Bundang-gu, Seongnam-si, Gyeonggi-do, Korea
MEDIPOST Co., Ltd. CEO Yang, Yoon Sun
Business Registration No.: 211-86-61218
TEL : 82-2-3465-6650 / FAX : 82-2-3465-6688